165 related articles for article (PubMed ID: 30746510)
1. The Potential for Mammographic Breast Density Change as a Biosensor of Adjuvant Tamoxifen Therapy Adherence and Response.
Mullooly M; Gierach GL
JNCI Cancer Spectr; 2018 Nov; 2(4):pky072. PubMed ID: 30746510
[No Abstract] [Full Text] [Related]
2. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer.
Eriksson L; He W; Eriksson M; Humphreys K; Bergh J; Hall P; Czene K
JNCI Cancer Spectr; 2018 Oct; 2(4):pky071. PubMed ID: 31360886
[TBL] [Abstract][Full Text] [Related]
4. Time to Mammographic Density Decrease After Exposure to Tamoxifen.
Bäcklund M; Eriksson M; Hammarström M; Thoren L; Bergqvist J; Margolin S; Hellgren R; Wengström Y; Gabrielson M; Czene K; Hall P
Oncologist; 2022 Jul; 27(7):e601-e603. PubMed ID: 35605013
[TBL] [Abstract][Full Text] [Related]
5. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
Thorén L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Breast Cancer Res Treat; 2021 Dec; 190(3):451-462. PubMed ID: 34570302
[TBL] [Abstract][Full Text] [Related]
6. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC; Thorat MA; Cuzick J; Brentnall AR
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013091. PubMed ID: 34697802
[TBL] [Abstract][Full Text] [Related]
7. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
8. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Andersson TM; Crowther MJ; Czene K; Hall P; Humphreys K
Am J Epidemiol; 2017 Nov; 186(9):1065-1073. PubMed ID: 28633324
[TBL] [Abstract][Full Text] [Related]
9. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
11. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
12. Can tamoxifen cause a significant mammographic density change in breast parenchyma?
Konez O; Goyal M; Reaven RE
Clin Imaging; 2001; 25(5):303-8. PubMed ID: 11682285
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
14. Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.
Mullooly M; Pfeiffer RM; Nyante SJ; Heckman-Stoddard BM; Perloff M; Jatoi I; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Berrington de Gonzalez A; Sherman ME; Gierach GL
J Clin Oncol; 2016 Jun; 34(18):2093-7. PubMed ID: 27022110
[No Abstract] [Full Text] [Related]
15. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen in women with breast cancer and mammographic density.
Meggiorini ML; Labi L; Vestri AR; Porfiri LM; Savelli S; De Felice C
Eur J Gynaecol Oncol; 2008; 29(6):598-601. PubMed ID: 19115686
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies.
Shawky MS; Martin H; Hugo HJ; Lloyd T; Britt KL; Redfern A; Thompson EW
Oncotarget; 2017 Jan; 8(3):5578-5591. PubMed ID: 27894075
[TBL] [Abstract][Full Text] [Related]
18. Effect of tamoxifen on breast tissue density in premenopausal breast cancer.
Slanetz PJ; Grandpre LE; Yeh ED; Kopans DB; Mendel JB
Breast J; 2004; 10(1):27-32. PubMed ID: 14717756
[TBL] [Abstract][Full Text] [Related]
19. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.
Atkinson C; Warren R; Bingham SA; Day NE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):863-6. PubMed ID: 10548313
[TBL] [Abstract][Full Text] [Related]
20. Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy.
Shia WC; Lin LS; Wu HK; Chen CJ; Chen DR
Cancer Control; 2023; 30():10732748231160991. PubMed ID: 36866691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
